Skip to Content
Merck
All Photos(1)

Key Documents

870853P

Avanti

ST1326

Avanti Polar Lipids 870853P, powder

Synonym(s):

(R)-3-(3-tetradecylureido)-4-(trimethylammonio)butanoate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H45 N3O3
CAS Number:
Molecular Weight:
399.61
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 1 mg (870853P-1mg)

manufacturer/tradename

Avanti Polar Lipids 870853P

lipid type

bioactive lipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

[O-]C(C[C@@H](NC(NCCCCCCCCCCCCCC)=O)C[N+](C)(C)C)=O

InChI

1S/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)

InChI key

BMZYTDRMCBZVNH-UHFFFAOYSA-N

General description

ST1326 contains an aliphatic carbon chain and is structurally similar to palmitoylcarnitine.

Biochem/physiol Actions

ST1326 is a reversible inhibitor of carnitine palmitoyltransferases. It shows anti tumor action in leukemia cell lines.

Packaging

5 mL Amber Glass Screw Cap Vial (870853P-1mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

also commonly purchased with this product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

No data available

Flash Point(C)

No data available


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Structural insight into function and regulation of carnitine palmitoyltransferase
Rufer AC, et al.
Cellular and Molecular Life Sciences, 66(15), 2489-2501 (2009)
A brain-liver circuit regulates glucose homeostasis
Pocai A, et al.
Cell Metabolism, 1(1), 53-61 (2005)
The carnitine system and cancer metabolic plasticity
Beatrice MMA, et al.
Cell Death & Disease, 9(2), 228-228 (2018)
Ida Sofie Grønningsæter et al.
Cells, 9(5) (2020-05-13)
Acute myeloid leukemia (AML) is an aggressive blood cancer resulting in accumulation of immature, dysfunctional blood cells in the bone marrow. Changes in cell metabolism are features of many cancers, including AML and this may be exploited as a therapeutic

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service